ReviewCurrent opinion in hematology2010
Erythropoietin receptor response circuits.
Review in Current opinion in hematology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 54 citations in OpenAlex.
- A transcriptional network governing ceramide homeostasis establishes a cytokine-dependent developmental process.Nature communications · 2023Article
- Disruption of stem cell niche-confined R-spondin 3 expression leads to impaired hematopoiesis.Blood advances · 2023Article
- The Latest Evidence of Erythropoietin in the Treatment of Glaucoma.International journal of molecular sciences · 2022Review
- Article
- Intermittent Caloric Restriction Promotes Erythroid Development and Ameliorates Phenylhydrazine-Induced Anemia in Mice.Frontiers in nutrition · 2022Article
- Identification of RHEX as a novel biomarker related to progression and immunity of non-small cell lung carcinoma.Translational cancer research · 2021Article
- Review
- Erythropoietin regulation of red blood cell production: from bench to bedside and back.F1000Research · 2020Review
- [Diagnostics and treatment of preoperative anemia].Der Anaesthesist · 2019Review
- Integrating Enhancer Mechanisms to Establish a Hierarchical Blood Development Program.Cell reports · 2017Article
- Epo reprograms the epigenome of erythroid cells.Experimental hematology · 2017Article
- Novel roles for podocalyxin in regulating stress myelopoiesis, Rap1a, and neutrophil migration.Experimental hematology · 2017Article
- Advances in understanding the mechanisms of erythropoiesis in homeostasis and disease.British journal of haematology · 2016Review
- In vivo regulation of erythropoiesis by chemically inducible dimerization of the erythropoietin receptor intracellular domain.PloS one · 2015Article
- RHEX, a novel regulator of human erythroid progenitor cell expansion and erythroblast development.The Journal of experimental medicine · 2014Article
- Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production.Hematology/oncology clinics of North America · 2014Review
- The influence of the pleiotropic action of erythropoietin and its derivatives on nephroprotection.Medical science monitor : international medical journal of experimental and clinical research · 2013Review
- Establishment of a cell-type-specific genetic network by the mediator complex component Med1.Molecular and cellular biology · 2013Article
- Erythropoietin: multiple targets, actions, and modifying influences for biological and clinical consideration.The Journal of experimental medicine · 2013Review
- Erythropoietin-directed erythropoiesis depends on serpin inhibition of erythroblast lysosomal cathepsins.The Journal of experimental medicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewIn 1985-1989, erythropoietin (EPO), its receptor (EPOR), and janus kinase 2 were cloned; established to be essential for definitive erythropoiesis; and initially intensely studied. Recently, new impetus, tools, and model systems have emerged to re-examine EPO/EPOR actions, and are addressed in this review. Impetus includes indications that EPO affects significantly more than standard erythroblast survival pathways, the development of novel erythropoiesis-stimulating agents, increasing evidence for EPO/EPOR cytoprotection of ischemically injured tissues, and potential EPO-mediated worsening of tumorigenesis. RECENT
findingsNew findings are reviewed in four functional contexts: (pro)erythroblast survival mechanisms, new candidate EPO/EPOR effects on erythroid cell development and new EPOR responses, EPOR downmodulation and trafficking, and novel erythropoiesis-stimulating agents. SUMMARY: As Current Opinion, this monograph seeks to summarize, and provoke, new EPO/EPOR action concepts. Specific problems addressed include: beyond (and before) BCL-XL, what key survival factors are deployed in early-stage proerythroblasts? Are distinct EPO/EPOR signals transduced in stage-selective fashions? Is erythroblast proliferation also modulated by EPO/EPOR signals? What functions are subserved by new noncanonical EPO/EPOR response factors (e.g. podocalyxin like-1, tribbles 3, reactive oxygen species, and nuclear factor kappa B)? What key regulators mediate EPOR inhibition and trafficking? And for emerging erythropoiesis-stimulating agents, to what extent do activities parallel EPOs (or differ in advantageous, potentially complicating ways, or both)?
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.